AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

This study is testing a combination of an experimental immunotherapy drug (AK112, which targets both PD-1 and VEGF) with standard chemotherapy as a first-line treatment for patients with metastatic colorectal cancer (cancer that has spread to other organs). Researchers want to see if adding this immunotherapy improves outcomes compared to chemotherapy alone. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with metastatic colorectal adenocarcinoma confirmed by biopsy - Your cancer is not treatable with surgery or local therapy - You have not previously received chemotherapy for metastatic disease (neoadjuvant therapy is allowed if it ended more than 12 months ago) - You have at least one measurable tumor area and are in good overall health (ECOG 0-1) **You may NOT be eligible if...** - You have received prior systemic treatment for metastatic colorectal cancer - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.